Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Denali Therapeutics (DNLI) EBITDA Margin: 2018-2023

Historic EBITDA Margin for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2023 value amounting to -7,779.24%.

  • Denali Therapeutics' EBITDA Margin fell 488860.00% to -7,779.24% in Q3 2023 from the same period last year, while for Sep 2023 it was -33.22%, marking a year-over-year increase of 25036.00%. This contributed to the annual value of -41.66% for FY2023, which is 26294.00% up from last year.
  • Per Denali Therapeutics' latest filing, its EBITDA Margin stood at -7,779.24% for Q3 2023, which was down 12,504.13% from 62.71% recorded in Q2 2023.
  • In the past 5 years, Denali Therapeutics' EBITDA Margin registered a high of 77.22% during Q4 2020, and its lowest value of -7,779.24% during Q3 2023.
  • Its 3-year average for EBITDA Margin is -1,419.73%, with a median of -617.22% in 2021.
  • Per our database at Business Quant, Denali Therapeutics' EBITDA Margin skyrocketed by 293,334bps in 2019 and then tumbled by 488,860bps in 2023.
  • Denali Therapeutics' EBITDA Margin (Quarterly) stood at -1,160.89% in 2019, then spiked by 123,811bps to 77.22% in 2020, then tumbled by 69,444bps to -617.22% in 2021, then slumped by 29,410bps to -911.32% in 2022, then crashed by 488,860bps to -7,779.24% in 2023.
  • Its EBITDA Margin was -7,779.24% in Q3 2023, compared to 62.71% in Q2 2023 and -299.97% in Q1 2023.